PRELUDE THERAPEUTICS INC Right-of-Use Asset Obtained in Exchange for Finance Lease Liability
PRELUDE THERAPEUTICS INC (PRLD) reported Right-of-Use Asset Obtained in Exchange for Finance Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability · last filed 2026-03-10
- PRELUDE THERAPEUTICS INC right-of-use asset obtained in exchange for finance lease liability for the quarter ending 2025-12-31 was $0.00.
- PRELUDE THERAPEUTICS INC right-of-use asset obtained in exchange for finance lease liability for the quarter ending 2024-12-31 was $0.00.
- PRELUDE THERAPEUTICS INC right-of-use asset obtained in exchange for finance lease liability for the quarter ending 2024-09-30 was $0.00.
- PRELUDE THERAPEUTICS INC right-of-use asset obtained in exchange for finance lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC right-of-use asset obtained in exchange for finance lease liability for fiscal 2024 was $603.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Finance Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Finance Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Finance Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Finance Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 10-K · filed 2026-03-10 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $603.00K 10-K · filed 2026-03-10 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $603.00K 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $603.00K 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |